An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma.

Authors:
Qiu Q; Chen S; He H; Chen J; Ding X and 10 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.06.010

PMCID:
PMC10692361

PMID:
38045037

Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest The authors have no conflicts of interest to declare."

Evidence found in paper:

"This work was supported by the 10.13039/501100001809National Natural Science Foundation of China (No.81773911, 81690263, and 81573616), and the Development Project of Shanghai Peak Disciplines-Integrated Medicine (No.20180101). We thank Shengsheng Xie and the staff of the National Facility for Protein Science in Shanghai (NFPS) for valuable technical support. We sincerely thank Qiuyue Han and Yuqi Zhu for their great help with MRI imaging, Songlei Zhou and Yiwen Zhang for their guidance on the establishment of the recurrent GBM model, Yihui Deng and Huining He for their experience in immunotherapy, and Mengting Yang for the guidance on GBM cell culture."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025